TSE:GUD FY2027 EPS Raised by Raymond James Financial

Knight Therapeutics Inc. (TSE:GUD - Free Report) - Stock analysts at Raymond James Financial raised their FY2027 earnings per share estimates for Knight Therapeutics in a research note issued on Wednesday, June 18th. Raymond James Financial analyst M. Freeman now anticipates that the company will post earnings per share of $0.17 for the year, up from their previous estimate of $0.15. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Raymond James Financial also issued estimates for Knight Therapeutics' FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.35 EPS.

GUD has been the topic of a number of other reports. Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics and gave the stock a "buy" rating in a research report on Friday, May 9th. Stifel Nicolaus lifted their target price on Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Finally, Research Capitl raised Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 11th. Two analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Strong Buy" and a consensus target price of C$7.15.

Knight Therapeutics Stock Performance

GUD stock traded down C$0.04 during trading on Monday, reaching C$5.81. 8,767 shares of the stock were exchanged, compared to its average volume of 67,861. Knight Therapeutics has a twelve month low of C$5.09 and a twelve month high of C$6.45. The company has a market capitalization of C$587.68 million, a P/E ratio of -19.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The stock has a 50 day simple moving average of C$5.87 and a 200-day simple moving average of C$5.70. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.